Alemtuzumab: evidence for its potential in relapsing-remitting multiple sclerosis.

Brown, J William L; Coles, Alasdair J

Brown, J William L; Coles, Alasdair J.

Affiliation

Brown JW; Department of Clinical Neurosciences, University of Cambridge, Cambridge, UK.

Drug Des Devel Ther ; 7: 131-8, 2013.

Article in En | MEDLINE | ID: mdl-23494602

Subject(s)

Adjuvants, Immunologic/therapeutic use; Antibodies, Monoclonal, Humanized/therapeutic use; Multiple Sclerosis, Relapsing-Remitting/drug therapy; Adjuvants, Immunologic/adverse effects; Alemtuzumab; Antibodies, Monoclonal, Humanized/adverse effects; Antibodies, Monoclonal, Humanized/immunology; Antigens, CD/immunology; Antigens, Neoplasm/immunology; CD52 Antigen; Glycoproteins/immunology; Humans; Interferon beta-1a; Interferon-beta/adverse effects; Interferon-beta/pharmacology; Interferon-beta/therapeutic use; Multiple Sclerosis, Relapsing-Remitting/immunology; Multiple Sclerosis, Relapsing-Remitting/physiopathology; Treatment Outcome

Key words

Campath; alemtuzumab; efficacy; relapsingremitting multiple sclerosis

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Adjuvants, Immunologic / Multiple Sclerosis, Relapsing-Remitting / Antibodies, Monoclonal, Humanized Type of study: Clinical_trials Limits: Humans Language: En Journal: Drug Des Devel Ther Journal subject: FARMACOLOGIA / TERAPIA POR MEDICAMENTOS Year: 2013 Document type: Article Affiliation country: United kingdom Country of publication: New Zealand

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google